Intraoperative Dobutamine Reduced Postoperative AKI After Septic Shock Source Control
In adults with septic shock undergoing surgical source control, intraoperative dobutamine added to norepinephrine lowered the risk of new-onset or worsening acute kidney injury during the first 7 postoperative days. The randomized trial enrolled 584 patients across 39 tertiary hospitals in China and tested a question with immediate bedside relevance: whether augmenting cardiac output during the operation could blunt the renal injury that often follows septic shock, vasopressor exposure, and major source-control surgery.
The answer was clinically favorable for the inotrope-vasopressor combination. AKI occurred in 22.8% of patients assigned to dobutamine plus norepinephrine, compared with 34.7% assigned to norepinephrine alone. The adjusted risk ratio was 0.64, with a 95% confidence interval of 0.49 to 0.83. In a syndrome where renal perfusion can fall despite adequate blood pressure, a therapy that improves forward flow may matter as much as pressure support itself.
Renal Protection Appeared Early, with Fewer Severe AKI Stages
The renal signal was not limited to the composite outcome. Stage 2 AKI occurred in 4.8% of patients in the dobutamine arm and 9.9% in the norepinephrine-only arm, while stage 3 AKI occurred in 7.9% and 13.6%, respectively. Those differences matter because progression into more severe KDIGO stages usually signals deeper tubular injury, longer recovery, and a higher likelihood of dialysis, prolonged intensive care, or delayed postoperative stabilization.
Hemodynamic physiology likely explains the renal benefit
Dobutamine increases myocardial contractility and can raise cardiac output, which may improve renal blood flow when septic shock has depressed effective perfusion despite vasopressor-driven arterial pressure. Norepinephrine remains central for vasoplegia, but restoring pressure alone does not necessarily reverse microcirculatory compromise or low-flow states. The combination strategy appears aimed at both sides of the septic circulation problem: vascular tone and forward pump function.
Early postoperative physiology moved in the same direction as the kidney outcomes. The Sequential Organ Failure Assessment score on postoperative day 1 was lower in the dobutamine group, with an adjusted difference of -0.53. Urine output 1 hour after the intervention was also higher, with an adjusted difference of 0.55 mL/kg/h. A brisker urine output so soon after treatment does not guarantee durable renal protection, but in this trial it aligned with the later AKI separation and provides a plausible bedside marker of improved organ perfusion.
Safety Tradeoff Centered on Tachycardia
The hemodynamic gain came with a predictable adverse effect profile. Tachycardia, defined as heart rate above 100 beats per minute, occurred more often in patients receiving dobutamine plus norepinephrine than in those receiving norepinephrine alone. For anesthesiologists and intensivists, this is the most immediate caution: an inotrope can improve perfusion while also increasing myocardial oxygen demand and provoking rate-related instability in vulnerable septic patients.
No significant differences emerged in 9 of the 11 secondary outcomes. That pattern tempers enthusiasm for broad claims of global organ rescue. The trial delivered a clear renal signal and a modest early SOFA advantage, but it did not translate into consistent benefit across the wider secondary endpoint set.
What the Trial Adds to Septic Shock Care in the Operating Room
The study directly addresses a gap left by guidelines that recommend dobutamine for septic shock with cardiac dysfunction and persistent hypoperfusion, yet rest on very low-certainty evidence. Until now, randomized data on intraoperative dobutamine combined with norepinephrine during surgical source control have been absent. This trial moves the question from theoretical physiology into a multicenter randomized clinical setting.
The enrolled population was older, with a median age of 67.5 years, and just under one-third were female. Those demographics fit the clinical reality of severe sepsis requiring operative source control, where baseline physiologic reserve is often limited and organ cross-talk is common. In that setting, renal injury is rarely isolated; it reflects the combined burden of inflammation, vasodilation, microvascular dysfunction, and perioperative stress.
The trial was open-label, which is unavoidable in many intraoperative hemodynamic studies but still leaves room for treatment-aware behavior around fluid administration, vasopressor titration, and postoperative management. Follow-up ended on November 15, 2025, and the primary endpoint focused on 7-day kidney outcomes rather than long-term renal recovery, dialysis dependence, or mortality. Those boundaries matter when translating the findings to practice.
Even with those constraints, the direction of effect is hard to ignore. Among patients already at high risk for postoperative organ dysfunction, adding dobutamine to norepinephrine reduced the chance of renal deterioration and improved early postoperative perfusion markers. The result argues for a more nuanced approach to intraoperative septic shock management, one that does not stop at restoring blood pressure but also asks whether the heart is delivering enough flow to protect the kidney.
The remaining clinical question is not whether dobutamine can move renal endpoints in this setting; it did. The harder issue is how to select the right patient, the right dose ceiling, and the right hemodynamic trigger while avoiding tachycardia in a population already under severe physiologic strain. The trial registration number is NCT06462313, and the field now needs outcomes that extend beyond early postoperative AKI to determine whether this strategy changes recovery in a durable way.